Reaz Mahmud, MS
Member
EuGEF Research Group
Mr. Reaz Mahmud received his BSc and MS degree from the Department of Biochemistry and Molecular Biology, University of Chittagong, Bangladesh, and started his research carrier in February 2014 at Laboratory of Eukaryotic Gene Expression and Function(EuGEF), BMB, CU. At EuGEF, he is involved in number of projects. In primary stage, he focused on the demographic frequency of breast cancer as well as molecular diversity in breast cancer under the supervision of Dr. ASM Noman to observe the expression pattern of several oncogenes at BRCA1 and BRCA2 expressed and/or mutated Breast cancer. Now, he is working at EuGEF Lab to find novel mutation of regulatory factor in cancer pathogenesis under the supervision of Drs. ASM Noman, MM Hossain, and S. Chowdhury. Besides, he is aiming to explore the role of epigenetic changes in down-regulation of miR-4726 in HER-2 positive breast cancer.
In free time, he likes to read novels, poetry and news of the world. He enjoys his leisure time with family and friends.
Selected Publications:
-
Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z, Rashid MI, Azad AK, Rahman ML, Barua D, Sultana A, Shirin A, Ferdous J, Parag RR, Rahman SM,Mahmud MR, Jerin CS, et al., Scientific Reports. 2017 May 11;7(1):1796;doi: 10.1038/s41598-017-01268-4; PMID: 28496132
-
Widespread expression of Sonic hedgehog(Shh)and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer. Noman AS, Parag RR, Rashid MI, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, Shirin A, Nayeem J, Mahmud R, Akther S, Shil RK, et al.,Therapeutic Advances in Medical Oncology. 2020 Mar 13;12:1758835920911229;doi: 10.1177/1758835920911229; PMID: 32206093
-
Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation. Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, Sultana A, Jerin C, Siddiqua A, Rahman L, Nayeem J, Akther S, Baidya S, Shil RK, Rahman M, Shirin A, Mahmud R, Hossain SMI, Sumi SA, et al.,Cell Death & Disease. 2020 Aug 20;11(8):663;doi: 10.1038/s41419-020-02907-x;PMID: 3281477